Bridgebio Pharma, Inc. (BBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$74.84-0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · BBIO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -15.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 91.3% |
Growth built into the price is above our model estimate.
The price assumes 107.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is on a run of consecutive earnings misses and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
BBIO — government funding
Dated 2026-08-31
Other Events. On August 31, 2026, BridgeBio Pharma, Inc. (the “Company”) issued a press release titled, “BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The Company expects its pricing commitment for its future medicines under its agreement with the U.S. government to exclude medicines a…
Why it matters: Earnings results will show if revenue growth continues and if operating losses improve. Investors will focus on these metrics.
Watch forRevenue for Q2 2026 exceeds $200 million, indicating strong growth.
Also watch forRevenue for Q2 2026 falls below $180 million, suggesting growth issues.
Why it matters: A successful buyback shows confidence in the company and helps the stock price.
Supportive ifThe company will finish $200 million in share buybacks by Q3 2026.
Worry ifNo major share buybacks are expected by Q3 2026.
Why it matters: Approval of encaleret would mark a major milestone for BridgeBio and its pipeline. It could transform treatment for ADH1 patients, opening a new revenue stream.
Supportive ifThe FDA approves the NDA for encaleret. This lets BridgeBio launch the product.
Worry ifFDA rejects the NDA for encaleret, delaying or halting its market entry.
Why it matters: This submission is important for BridgeBio's growth. It may lead to future revenue from achondroplasia treatments.
Supportive ifBridgeBio submits the NDA for infigratinib by the end of Q3 2026.
Worry ifNDA submission for infigratinib is delayed beyond Q3 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$129 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $375 loss on $10,000 · 3.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,025 loss on $10,000 · 20.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Operating losses affect financial health. A reduction shows that costs are managed better.
Worry ifOperating losses decrease to less than $100 million in Q2 2026.
Less concerning ifOperating losses stay above $110 million in Q2 2026. This shows ongoing problems.
Why it matters: Positive trial results could validate BBP-418 as a leading treatment for LGMD2I/R9 and support future revenue growth.
Watch forBridgeBio shares good results from BBP-418 clinical trials.
Also watch forBBP-418 trials show poor results or big delays.
Why it matters: This event will give clues about BridgeBio's plans for three new products. This could change how investors feel.
Watch forGood comments on being ready to launch and strategies were shared during the event.
Also watch forNegative feedback or lack of clarity on launch strategies during the event.
Why it matters: Active buybacks may show that management believes in the company's value. This can help the share price. It is part of their capital strategy.
Supportive ifBridgeBio starts share buybacks under the $500 million program.
Worry ifNo buybacks are initiated within the next six months.
Why it matters: More revenue from Attruby is key for BridgeBio's finances and future products.
Supportive ifAttruby revenue grows year over year by more than 20% in Q3 2026.
Worry ifAttruby revenue growth falls below 10% year over year in Q3 2026.
Why it matters: This date is crucial for encaleret, which could become the first approved therapy for ADH1. Approval may enhance market position.
Supportive ifFDA approval of encaleret by the PDUFA date of May 8, 2027.
Worry ifDelay or rejection of encaleret's NDA by the FDA.
Why it matters: New data could help Attruby compete better against tafamidis. This may affect investor trust.
Supportive ifLook for new proof that shows Attruby is better than tafamidis.
Worry ifWatch for no new data or negative results published.
Why it matters: If BBP-418 gets approved, it will be a big step for BridgeBio. It could show that the company is meeting needs in LGMD2I/R9.
Supportive ifFDA approves BBP-418 for LGMD2I/R9 ahead of or on the PDUFA date.
Worry ifFDA rejects BBP-418 or delays the decision beyond the PDUFA date.